DAI-NIPPON-PRINTING
31.8.2021 03:02:06 CEST | Business Wire | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has developed a Reflect Array that flexibly reflects the millimetre waves used in fifth generation (5G) mobile communications systems to expand coverage area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005245/en/
Compared to general metal reflectors, the new product is capable of reflecting millimetre waves in a more targeted manner. As a result, there are fewer restrictions on installation, making it possible to improve the communications environment in locations where radio waves have been difficult to reach, such as those in the shadow of buildings. In addition, the new product boasts superior design features allowing it to respond to various installation environment considerations.
Background
The 24GHz and above radio waves used in the high-speed large-capacity communications of 5G are higher frequency milliwaves than those used in 4G, and maintain a larger information capacity. At the same time, they are characterized by strong straightness properties and short reach, leading to radio waves being blocked in areas such as in the shadow of buildings making it difficult to ensure communication quality. Also, when adding base stations and relay equipment to resolve this issue, new challenges emerge, such as large costs and the difficulty of securing installation space.
DNP has once again risen to the challenge, taken advantage of proprietary microfabrication technology, and by applying an original concept has successfully separated the Frequency Selection Reflection Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, and the Reflective Direction Control Layer, a special dielectric layer that decides the direction of incoming and reflected radio waves, to develop a Reflect Array that makes it easier to control for the characteristics of each layer. The newly developed product is cheaper than installing base stations and relay equipment, and does not require a power source. It can, therefore, be installed in a variety of location, which contributes to significant improvements in the 5G communications environment.
Features
- Can be installed in a variety of locations
Unlike metal reflectors that reflect radio waves directly as in a mirror, the newly developed product is a reflective array capable of the asymmetric reflection of specific frequency radio waves. It is possible to flexibly set the frequency band to be reflected, the incidence angle of the radio waves received from the base station, and the reflection angle to deliver the radio waves, along with the spread of the reflection waves. As a result, it is now possible to effectively deliver radio waves to locations where it was previously difficult to do so. As a power source is no longer needed the new product can also be used in locations where installation space is restricted.
- Effective designs based on original concepts
The new product is comprised of three layers: the Frequency Selective Surface Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, the Reflective Direction Control Layer that decides the direction of incoming and reflected radio waves, and a Design Cover Layer that not only protects these two layers, but also provides the durability required of construction materials along with high level design features that are conducive to various installation environment considerations.
- Effective improvement of radio wave conditions
We have made it is possible to pre-adjust the spread of the reflection waves in answer to the desire to deliver reflection waves over a broad area, or to gather those waves into specific devices.
- Reduces the impact on existing radio waves
Unlike metal reflectors that reflect all radio waves, the new product passes through all but target radio waves, reducing the impact on existing radio waves.
- Superior design features
It is possible to print various patterns on the surface of the Design Cover Layer, making it possible to add external designs, including interior, exterior and advertising signboards.
Usage Scene
Recently, we have seen more companies and organizations consider the adoption of 5G as a means of targeting the realization of smart cities and smart factories that exploit robots and the Internet of Things (IoT). Commercialization efforts are already underway. With the development of the Reflect Array, we anticipate the following installation instances in cases where the radio wave environment is expected to deteriorate due to obstacles, and aim to link these initiatives to the spread of 5G.
- Improvement of the communication environment behind radio wave shields in smart factories
- Improvement of mobile device usage environment indoors at business offices and educational sites
- Usage at exhibition spaces where layouts change with each event and radio wave shielding conditions alter
- Usage at stadiums and amusement facilities where area-specific information is delivered
- Applications leveraging design elements, such as urban buildings, walls and signboards that require harmony with the surrounding environment
Looking Ahead
DNP will work jointly with various communications-related companies, including communications carriers, to verify the functionality of the new product, aiming for commercialization from FY 2023.
The new product is a Passive type Reflect Array that fixes the reflection direction of the radio waves. We will engage in joint development of an Active type Reflect Array with multiple companies, and this research has been selected as a national project in FY2021.
About DNP
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
